A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

NCT06615206 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
6
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

HuidaGene Therapeutics Co., Ltd.

Collaborators